Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCEADE-CRC-03: Phase 3 study of precemtabart tocentecan with/without bevacizumab vs trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer
jRCT2031260267Phase 3Recruiting
- Sponsor
- Merck KGaA
- Start
- Jun 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of precemtabart tocentecan in metastatic colon cancer (mCRC) (3 arms), sponsored by Merck KGaA. Primary endpoint: Overall Survival. Started Jun 2026; status: recruiting.
02
Drugs
precemtabart tocentecan
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on jRCT2031260267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260267.